HAS-BLED Score Calculator
HAS-BLED Score Calculator
Bleeding risk on anticoagulation for atrial fibrillation, with the two doubled letters scored properly. A high score flags what to correct and who to review — it is not a reason to withhold anticoagulation.
HAS-BLED Score
9 items → 0–9Uncontrolled hypertension (1); abnormal renal function (1); abnormal liver function (1); age over 65 (1); taking an antiplatelet (1)
Scoring
Maximum 9. A score of 3 or more is conventionally described as high risk.
- A is worth up to 2
- abnormal renal function and abnormal liver function are scored separately. A patient with cirrhosis and a creatinine above 200 µmol/L scores 2 from this letter alone, and a calculator offering one combined checkbox reports 1
- D is worth up to 2
- concomitant antiplatelet or NSAID use scores 1 and alcohol at 8 or more units a week scores another. Same structure, same error: collapsing the letter loses a point
- why that matters at the threshold
- a patient with renal dysfunction, liver dysfunction and an antiplatelet scores 3 on the published instrument — high risk — and 2 on a collapsed implementation. The under-scoring crosses the only threshold the instrument has
- 3 or more is high risk
- and high risk means shorter review intervals and a plan to correct the modifiable factors. It does not mean withhold anticoagulation: the score was designed to flag correctable risk, not to select people to leave untreated
Worked example
Uncontrolled hypertension (1); abnormal renal function (1); abnormal liver function (1); age over 65 (1); taking an antiplatelet (1)
H 1 + A 2 + E 1 + D 1 = 5 points
The A letter contributes 2, not 1 — renal and liver function are scored separately
The D letter contributes 1 here, and would contribute 2 if this patient also drank 8 or more units a week
5 is at or above 3, so this is a high bleeding risk. That means a shorter review interval, a plan to get the systolic below 160, and a hard look at whether the antiplatelet is still needed — not stopping the anticoagulant
An implementation that collapses A into a single checkbox returns 4 for this patient. On a patient whose only risk factors were renal dysfunction, liver dysfunction and an antiplatelet it would return 2 against the published 3, and report a high-risk patient as low risk
The nine items — note that A and D are two each
| Letter | Criterion | Definition | Points |
|---|---|---|---|
| H | Hypertension | Uncontrolled, systolic above 160 mmHg | 1 |
| A | Abnormal renal function | Dialysis, transplant, or creatinine ≥200 µmol/L | 1 |
| A | Abnormal liver function | Cirrhosis, or bilirubin >2× normal with AST/ALT/ALP >3× normal | 1 |
| S | Stroke | Previous stroke, particularly lacunar or haemorrhagic | 1 |
| B | Bleeding | Previous major bleed, or a predisposition — anaemia, thrombocytopenia | 1 |
| L | Labile INRs | Time in therapeutic range under 60%, on a vitamin K antagonist | 1 |
| E | Elderly | Age over 65 | 1 |
| D | Drugs | Concomitant antiplatelet agent or NSAID | 1 |
| D | Alcohol | Eight or more units per week | 1 |
What to do with each point scored
| Risk factor | Modifiable? | Action |
|---|---|---|
| Uncontrolled hypertension | Yes | Treat to a systolic below 160 mmHg — the single most correctable item on the list |
| Labile INRs | Yes | Improve time in therapeutic range, or switch to a direct oral anticoagulant, which removes the item entirely |
| Antiplatelet or NSAID | Yes | Stop unless there is a compelling and current indication; combination therapy is a common and avoidable driver of bleeding |
| Alcohol at 8 or more units a week | Yes | Reduce intake; address hazardous drinking in its own right |
| Abnormal renal function | Partly | Avoid nephrotoxics, review the anticoagulant dose against renal function, monitor |
| Abnormal liver function | Partly | Treat the underlying liver disease; some direct oral anticoagulants are contraindicated in significant impairment |
| Bleeding history or anaemia | Partly | Investigate and treat the source — iron deficiency, H. pylori, a colonic lesion |
| Age over 65, previous stroke | No | Not correctable, and not a reason to withhold treatment — these raise stroke risk at least as much as bleeding risk |
A score that tells you what to fix, not who to leave untreated
HAS-BLED estimates the one-year risk of major bleeding in a patient anticoagulated for atrial fibrillation. Seven letters, nine scored items, one point each, maximum 9. The structure matters more than it looks: two of the letters cover two independent items. The A stands for abnormal renal function and abnormal liver function, scored separately, so that letter can contribute 2 points. The D stands for drugs predisposing to bleeding and alcohol, also separate, also worth up to 2. Implementations that offer one checkbox per letter are the commonest way this score is got wrong.
That error is not cosmetic, because the instrument has only one threshold. A patient with renal dysfunction, liver dysfunction and a concomitant antiplatelet scores 3 on the published score — high risk — and 2 on a collapsed implementation, which reports them as low risk. The under-scoring runs in the direction that removes a patient from closer review, and it is invisible on the page, because a total of 2 looks entirely plausible.
What a high score means is where most of the harm associated with this score has come from. A HAS-BLED of 3 or more is conventionally high risk, and it is not a reason to withhold anticoagulation. In almost every patient who has an indication, the strokes prevented outweigh the bleeds caused, and the factors that drive a high HAS-BLED — age, prior stroke, renal impairment — are largely the same factors that drive stroke risk. Using the score as a gate rather than a prompt withholds treatment from precisely the people with most to gain from it.
Used properly it does two useful things. It identifies the modifiable risk factors to correct: an uncontrolled blood pressure, an antiplatelet or NSAID with no current indication, hazardous drinking, poor INR control that could be improved or removed by switching to a direct oral anticoagulant. And it identifies the patients who should be seen sooner and more often, because a high score predicts events that early review can catch. The score informs those judgements; it does not make them, and no threshold in it should be read as a rule.
Frequently asked questions
What is a high HAS-BLED score?
Three or more is conventionally described as high risk. That should trigger a shorter review interval and a plan to correct the modifiable factors — blood pressure, antiplatelets and NSAIDs, alcohol, INR control — rather than a decision to stop or withhold anticoagulation.
Should anticoagulation be withheld if HAS-BLED is high?
No. In almost every patient with an indication, the strokes prevented outweigh the bleeds caused, and the factors driving a high HAS-BLED largely also drive stroke risk. The score exists to flag correctable bleeding risk and to identify who needs closer review, not to select people to leave untreated.
Why does HAS-BLED have nine items for seven letters?
Because two letters cover two things each. A is abnormal renal function and abnormal liver function, scored separately, and D is drugs predisposing to bleeding and alcohol, also separate. Each of those letters can therefore contribute 2 points, which is how the maximum reaches 9.
What is the maximum HAS-BLED score?
Nine. One point each for hypertension, stroke, bleeding history, labile INRs and age over 65, plus up to two for abnormal renal and liver function and up to two for drugs and alcohol.
Does the labile INR item apply on a direct oral anticoagulant?
No. There is no INR to monitor, so the item scores 0. That is one of the ways a high score can be lowered: a patient with poor time in therapeutic range on warfarin loses that point on switching, provided a direct oral anticoagulant is otherwise appropriate.
Related calculators
References
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
- Lane DA, Lip GYH. Use of the CHA₂DS₂-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation. Circulation. 2012;125(19):2298–2307.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.